Pfizer-BioNTech Covid-19 vaccine remains highly effective after six months, trial data show
The vaccine was 100 per cent effective against severe disease as defined by the United States (US) Centres for Disease Control and Prevention, and 95.3 per cent effective against severe COVID-19 as defined by the US Food and Drug Administration (FDA), according to a joint statement of the two companies.